title: Novel agents and biomarkers for acute lymphoid leukemia.
abstract: New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high rate of leukemic relapse in B-ALL. Although complete remission rates by induction chemotherapy in ALL are now high, the long-term survival is still disappointing. Improvements in the survival outcome of ALL have been observed in young adults as a result of the use of pediatric inspired regimens and the broadening of the number of patients who are eligible for allogeneic SCT. Development of new and less toxic agents also provide promise to improve the outcome in adult ALL, such as tyrosine kinase inhibitors in Ph-positive ALL, rituximab in CD20-positive disease, blinatumomab in precursor B-ALL and nelarabine in T-lineage ALL. Challenges for the future are to implement genomic profiling into the clinical setting to guide risk stratification and providing novel targets for tailored therapies.
authors.affiliation: Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang University, No, 79 Qing Chun Rd, Hangzhou 310003, China.
authors.forename: Yanmin
authors.initials: Y
authors.lastname: Zhao
authors.forename: He
authors.initials: H
authors.lastname: Huang
authors.forename: Guoqing
authors.initials: G
authors.lastname: Wei
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D018572:Disease-Free Survival; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor